StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –

Novartis Kisqali by Quarter

Kisqali — New Prescription (NBRx) Market Share in Metastatic Breast Cancer (mBC) in Top 10 Ex-US Markets (%)

Novartis Kisqali: 56.0% in Q3 2026, down 2.0 pts from a year earlier.

Latest, Q3 2026
56.0%
Period ended Sep 30, 2026
Change on a year earlier
-2.0 pts
58.0% in Q3 2025
History
7 quarters
Since Q1 2025
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“| 1,329 | 653 | • Continued mBC leadership in NBRx (56%)”

Source: Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗

Market share within the CDK4/6 inhibitor class published periodically on quarterly Kisqali product slides.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKisqali — New Prescription (NBRx) Market Share in Metastatic Breast Cancer (mBC) in Top 10 Ex-US Markets (%)Year on yearSource
Q3 2026Sep 30, 202656.0%-2.0 ptsNovartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗
Q2 2026Jun 30, 202654.0%+4.0 ptsNovartis Official IR / Sustainability Report — q2-2026-investor-presentation.pdf ↗
Q1 2026Mar 31, 202650.0%+4.0 ptsNovartis Official IR / Sustainability Report — q1-2026-investor-presentation.pdf ↗
Q4 2025Dec 31, 202550.0%–Novartis Official IR / Sustainability Report — q4-2025-investor-presentation.pdf ↗
Q3 2025Sep 30, 202558.0%–Novartis Official IR / Sustainability Report — q3-2025-investor-presentation.pdf ↗
Q2 2025Jun 30, 202550.0%–Novartis Official IR / Sustainability Report — q2-2025-investor-presentation.pdf ↗
Q1 2025Mar 31, 202546.0%–Novartis Official IR / Sustainability Report — q1-2025-investor-presentation.pdf ↗

Breakdown

What makes up kisqali

Cite this data

StockData. (2026). Novartis Kisqali (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rx-kisqali-exus-mbc-nbrx-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.